Work

Cytokine Release Syndrome and Neurotoxicity by Baseline Tumor Burden in Adults With Relapsed or Refractory Diffuse Large B‐cell Lymphoma Treated With Tisagenlecleucel

Year: 2019

Type: conference-abstract

Abstract: every two months (first year), every six months (years 2-3) and yearly thereafter.A FDG-PET study was performed at six weeks after treatment in all patients.Results: Forty-twopatients were enrolled, and 36 patients has completed a three-month assessment.The current overall objective response rate was 34 of 36 (94.4%) with 29 complete remissions (CRs) and 5 partial remissions (PRs).no severe toxicity was observed. Twenty-seven patients occurred Cytokine release syndrome (CRS).This clinical trial is ongoing (www.clinicaltrials.orgas NCT03097770).

Source: Hematological Oncology

DOI: 10.1002/hon.117_2630

Authors: R.T. Maziarz, S.J. Schuster, S.G. Ericson, E.S. Rusch, J. Signorovitch, J. Li, V.V. Romanov, D.G. Maloney, F.L. Locke

Institutions: OHSU Knight Cancer Institute, Abramson Cancer Center, University of Pennsylvania, Novartis (United States), Analysis Group (United States), Fred Hutch Cancer Center, Moffitt Cancer Center

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: GlaxoSmithKline, Celgene, Novartis Pharmaceuticals Corporation, Janssen Scientific Affairs, Incyte, Genentech, Juno Therapeutics

OpenAlex ID: W2952224846

Cites:

Cited by: 12

Related to: 10